NCT07257913 Impact of Dairy Integration Into Canadian Food Guide on Gut Health
| NCT ID | NCT07257913 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Laval University |
| Condition | Gut Epithelial Permeability |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-10-06 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-10-06 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective is to investigate the impact of milk, fermented milk, and soy beverages, incorporated in a diet reflecting adherence to Canadian food guide recommendations on food choices on gut microbiota in middle-aged adults (45-65 years) with abdominal obesity and slightly deteriorated lipids and/or glucose profile. The study aims to discern whether the integration of soy beverages (control), milk, and fermented milk within the CFG diet contributes to distinct gut outcomes and alterations in gut health. We hypothesized that milk and fermented milk will further promote beneficial changes in gut health parameters including gut microbiota composition, trans-epithelial permeability, and inflammation, relative to soy beverages.
Eligibility Criteria
Inclusion Criteria: * IMC \< 45 * Waist circumference \> 80 cm (Women) or 94 cm (men) Exclusion Criteria: * History of diabetes (types 1 and 2), CVD, enteropathy, immune diseases or bariatric surgery * Cancer (diagnostic and/or treatment) during the last 5 years * Antibiotic consumption during the last 3 months * Active smoking or cannabis consumption * Lactose intolerance or allergy, any allergies to foods given in the intervention phases * Irregular defecation patterns * Pregnancy/lactation * Inability to speak French
Contact & Investigator
Alain Veilleux, PhD
PRINCIPAL INVESTIGATOR
Laval University
Frequently Asked Questions
Who can join the NCT07257913 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 65 Years, studying Gut Epithelial Permeability. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07257913 currently recruiting?
Yes, NCT07257913 is actively recruiting participants. Contact the research team at alain.veilleux@fsaa.ulaval.ca for enrollment information.
Where is the NCT07257913 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT07257913 clinical trial?
NCT07257913 is sponsored by Laval University. The principal investigator is Alain Veilleux, PhD at Laval University. The trial plans to enroll 20 participants.